# Hemophilia B Gene Therapy With AAV8 Vector

> **NCT01620801** · PHASE1 · TERMINATED · sponsor: **Spark Therapeutics, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **BIOLOGICAL:** AAV8-hFIX19

## Key facts

- **NCT ID:** NCT01620801
- **Lead sponsor:** Spark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2019-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01620801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01620801, "Hemophilia B Gene Therapy With AAV8 Vector". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01620801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*